EGFR and non-small cell lung carcinoma: Two phase III studies with previously untreated patients with NSCLC who harbored EGFR-activating mutations demonstrated significant improvement in survival among gefitinib groups compared with platinum-based chemotherapy groups, and these findings established gefitinib as a standard treatment for EGFR-mutated NSCLC [5, 6].